Kisspeptin and GPR54 in Ovarian Cancer
Author Information
Author(s): Leah M Prentice, Christian Klausen, Steve Kalloger, Martin Köbel, Steven McKinney, Jennifer L Santos, Challayne Kenney, Erika Mehl, C Blake Gilks, Peter Leung, Ken Swenerton, David G Huntsman, Samuel AJ Aparicio
Primary Institution: British Columbia Cancer Research Centre and University of British Columbia
Hypothesis
The immunoreactivity of kisspeptin and GPR54 is associated with a better prognosis in ovarian carcinoma.
Conclusion
Kisspeptin and GPR54 immunoreactivity are significantly associated with favourable prognosis in ovarian clear cell carcinomas.
Supporting Evidence
- Kisspeptin and GPR54 positivity are associated with better survival outcomes.
- Kisspeptin is an independent marker for favourable prognosis.
- GPR54 is significantly associated with overall survival in clear cell subtype.
- Both proteins are linked to the clear cell subtype of ovarian carcinoma.
Takeaway
This study found that certain proteins in ovarian cancer can help predict how well patients will do, especially for a specific type of ovarian cancer called clear cell carcinoma.
Methodology
Immunohistochemical analysis was performed on a tissue microarray of 518 early stage ovarian carcinomas.
Limitations
The study may not generalize to all ovarian cancer subtypes due to the focus on clear cell carcinoma.
Participant Demographics
The cohort consisted of 518 patients with early stage ovarian carcinomas.
Statistical Information
P-Value
p = 0.0023, p = 0.0092, p = 0.0006, p = 0.0002, p = 0.0046, p = 0.0170, p = 0.0303, p < 0.0001
Confidence Interval
95% CI for risk ratios provided in tables
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website